Identification of a Novel Risk Locus for Progressive Supranuclear Palsy by a Pooled Genomewide Scan of 500,288 Single-Nucleotide Polymorphisms

To date, only the H1 MAPT haplotype has been consistently associated with risk of developing the neurodegenerative disease progressive supranuclear palsy (PSP). We hypothesized that additional genetic loci may be involved in conferring risk of PSP that could be identified through a pooling-based genomewide association study of 1 500,000 SNPs. Candidate SNPs with large differences in allelic frequency were identified by ranking all SNPs by their probe-intensity difference between cohorts. The MAPT H1 haplotype was strongly detected by this methodology, as was a second major locus on chromosome 11p12-p11 that showed evidence of association at allelic ( ), genotypic ( ), and haplotypic P ! .001 P ! .001 ( ) levels and was narrowed to a single haplotype block containing the DNA damage-binding protein 2 ( DDB2 ) P ! .001 and lysosomal acid phosphatase 2 ( ACP2 ) genes. Since DNA damage and lysosomal dysfunction have been implicated in aging and neurodegenerative processes, both genes are viable candidates for conferring risk of disease.

[1]  A. Myers,et al.  The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts , 2007, Neurobiology of Disease.

[2]  Rebecca F. Halperin,et al.  Identification of the genetic basis for complex disorders by use of pooling-based genomewide single-nucleotide-polymorphism association studies. , 2007, American journal of human genetics.

[3]  M. Esiri,et al.  Haplotype-specific expression of exon 10 at the human MAPT locus. , 2006, Human molecular genetics.

[4]  Sonja W. Scholz,et al.  Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data , 2006, The Lancet Neurology.

[5]  M. Farrer,et al.  Genomewide association, Parkinson disease, and PARK10. , 2006, American journal of human genetics.

[6]  R. Myers,et al.  Considerations for genomewide association studies in Parkinson disease. , 2006, American journal of human genetics.

[7]  A. Goris,et al.  No evidence for association with Parkinson disease for 13 single-nucleotide polymorphisms identified by whole-genome association screening. , 2006, American journal of human genetics.

[8]  Sonja W. Scholz,et al.  Conflicting results regarding the semaphorin gene (SEMA5A) and the risk for Parkinson disease. , 2006, American journal of human genetics.

[9]  J. Catanese,et al.  A case-control association study of the 12 single-nucleotide polymorphisms implicated in Parkinson disease by a recent genome scan. , 2006, American journal of human genetics.

[10]  M. Kapetanaki,et al.  The DDB1-CUL4ADDB2 ubiquitin ligase is deficient in xeroderma pigmentosum group E and targets histone H2A at UV-damaged DNA sites. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Robert Plomin,et al.  Genotyping pooled DNA using 100K SNP microarrays: a step towards genomewide association scans , 2006, Nucleic acids research.

[12]  Mariza de Andrade,et al.  High-resolution whole-genome association study of Parkinson disease. , 2005, American journal of human genetics.

[13]  G. Schellenberg,et al.  High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. , 2005, Human molecular genetics.

[14]  David W Craig,et al.  Identification of disease causing loci using an array-based genotyping approach on pooled DNA , 2005, BMC Genomics.

[15]  J. Cleaver.  Cancer in xeroderma pigmentosum and related disorders of DNA repair , 2005, Nature Reviews Cancer.

[16]  C. van Broeckhoven,et al.  Genomic architecture of human 17q21 linked to frontotemporal dementia uncovers a highly homologous family of low-copy repeats in the tau region. , 2005, Human molecular genetics.

[17]  Keiji Tanaka,et al.  UV-Induced Ubiquitylation of XPC Protein Mediated by UV-DDB-Ubiquitin Ligase Complex , 2005, Cell.

[18]  Nicola Pavese,et al.  Genetic linkage of autosomal dominant progressive supranuclear palsy to 1q31.1 , 2005, Annals of neurology.

[19]  A J Lees,et al.  Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration , 2005, Journal of Medical Genetics.

[20]  H. Stefánsson,et al.  A common inversion under selection in Europeans , 2005, Nature Genetics.

[21]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[22]  A. Syvänen,et al.  Silhouette scores for assessment of SNP genotype clusters , 2005, BMC Genomics.

[23]  W. Engel,et al.  Mutation in the gene encoding lysosomal acid phosphatase (Acp2) causes cerebellum and skin malformation in mouse , 2004, Neurogenetics.

[24]  A. Singleton,et al.  The tau H2 haplotype is almost exclusively Caucasian in origin , 2004, Neuroscience Letters.

[25]  I. Litvan.  Update on progressive supranuclear palsy , 2004, Current neurology and neuroscience reports.

[26]  Nicholas W Wood,et al.  The structure of the tau haplotype in controls and in progressive supranuclear palsy. , 2004, Human molecular genetics.

[27]  P. Pástor,et al.  Tau gene delN296 mutation, Parkinson's disease, and atypical supranuclear palsy , 2004, Annals of neurology.

[28]  A. Albanese,et al.  Progressive supranuclear palsy and Parkinson's disease in a family with a new mutation in the tau gene , 2004, Annals of neurology.

[29]  Erdahl T. Teber,et al.  Tau haplotypes regulate transcription and are associated with Parkinson's disease , 2004, Annals of neurology.

[30]  T. Hamamoto,et al.  Human DDB2 splicing variants are dominant negative inhibitors of UV-damaged DNA repair. , 2004, Biochemical and biophysical research communications.

[31]  J. Trojanowski,et al.  Paired helical filament tau (PHFtau) in Niemann-Pick type C disease is similar to PHFtau in Alzheimer's disease , 2004, Acta Neuropathologica.

[32]  B. Ghetti,et al.  Neurofibrillary tangles in Niemann-Pick disease type C , 2004, Acta Neuropathologica.

[33]  L. Thompson,et al.  Autophagy regulates the processing of amino terminal huntingtin fragments. , 2003, Human molecular genetics.

[34]  D. Dickson,et al.  Diagnostic accuracy of progressive supranuclear palsy in the Society for Progressive Supranuclear Palsy Brain Bank , 2003, Movement disorders : official journal of the Movement Disorder Society.

[35]  Jeremy N. Skepper,et al.  α-Synuclein Is Degraded by Both Autophagy and the Proteasome* , 2003, Journal of Biological Chemistry.

[36]  Stefan Kammerer,et al.  Association testing by DNA pooling: An effective initial screen , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[37]  D. Schaid,et al.  Score tests for association between traits and haplotypes when linkage phase is ambiguous. , 2002, American journal of human genetics.

[38]  G. Alexander,et al.  Apolipoprotein E and Intellectual Achievement , 2002, Journal of the American Geriatrics Society.

[39]  Richard J. Caselli,et al.  Preclinical cognitive decline in late middle-aged asymptomatic apolipoprotein E-e4/4 homozygotes: a replication study , 2001, Journal of the Neurological Sciences.

[40]  D W Dickson,et al.  Progressive supranuclear palsy as a disease phenotype caused by the S305S tau gene mutation. , 2001, Brain : a journal of neurology.

[41]  D. Dickson,et al.  Microglial Activation Parallels System Degeneration in Progressive Supranuclear Palsy and Corticobasal Degeneration , 2001, Journal of neuropathology and experimental neurology.

[42]  E. Tolosa,et al.  Familial atypical progressive supranuclear palsy associated with homozigosity for the delN296 mutation in the tau gene , 2001, Annals of neurology.

[43]  J. Jankovic,et al.  An extended 5′-tau susceptibility haplotype in progressive supranuclear palsy , 2000, Neurology.

[44]  M. Goedert,et al.  Tau mutations in familial frontotemporal dementia. , 2000, Brain : a journal of neurology.

[45]  P. Schofield,et al.  Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: expansion of the disease phenotype caused by tau gene mutations. , 2000, Brain : a journal of neurology.

[46]  A. Lees,et al.  Clinical genetics of familial progressive supranuclear palsy. , 1999, Brain : a journal of neurology.

[47]  M. Rossor,et al.  The tau gene A0 polymorphism in progressive supranuclear palsy and related neurodegenerative diseases , 1999, Journal of neurology, neurosurgery, and psychiatry.

[48]  I Litvan,et al.  Association of an extended haplotype in the tau gene with progressive supranuclear palsy. , 1999, Human molecular genetics.

[49]  J. Molinuevo,et al.  Significant changes in the tau A0 and A3 alleles in progressive supranuclear palsy and improved genotyping by silver detection. , 1998, Archives of neurology.

[50]  C. Peters,et al.  Mice Deficient in Lysosomal Acid Phosphatase Develop Lysosomal Storage in the Kidney and Central Nervous System* , 1997, The Journal of Biological Chemistry.

[51]  L. Thal,et al.  Genetic evidence for the involvement of τ in progressive supranuclear palsy , 1997, Annals of neurology.

[52]  M. Hallett,et al.  Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) , 1996, Neurology.

[53]  I Litvan,et al.  Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) , 1996, Neurology.

[54]  I Litvan,et al.  Validity and Reliability of the Preliminary NINDS Neuropathologic Criteria for Progressive Supranuclear Palsy and Related Disorders , 1996, Journal of neuropathology and experimental neurology.

[55]  I Litvan,et al.  Preliminary NINDS neuropathologic criteria for Steele‐Richardson‐Olszewski syndrome (progressive supranuclear palsy) , 1994, Neurology.

[56]  R. Brumback,et al.  Clinically asymptomatic xeroderma pigmentosum neurological disease in an adult: evidence for a neurodegeneration in later life caused by defective DNA repair. , 1993, European neurology.

[57]  M. Pappolla,et al.  Acid phosphatase activity in senile plaques and cerebrospinal fluid of patients with Alzheimer's disease. , 1993, Archives of pathology & laboratory medicine.

[58]  K. Figura,et al.  Human lysosomal acid phosphatase: cloning, expression and chromosomal assignment. , 1988, The EMBO journal.